These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 21061564)

  • 1. [A new anti-mycobacterial agent, rifabutin].
    Kurashima A; Mori T; Tomono Y; Abe S; Nagaoka M; Abe M
    Kekkaku; 2010 Oct; 85(10):743-56. PubMed ID: 21061564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Studies on therapeutic efficacy of a new anti-tuberculous drug, benzoxazinorifamycin, against murine experimental mycobacterial infections: attempt at various regimens and protocols].
    Tomioka H; Saito H
    Kekkaku; 1994 Nov; 69(11):703-10. PubMed ID: 7837724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical experience using rifabutin for treating infection with Mycobacterium tuberculosis in elderly Japanese patients].
    Morimoto K; Yoshiyama T; Kuse M; Okumura M; Sasaki Y; Yoshimori K; Ogata H; Kurashima A; Kudoh S
    Kekkaku; 2013 Aug; 88(8):625-8. PubMed ID: 24044166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [In vitro activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis].
    Sato K; Tomioka H; Saito H; Kawahara S; Hidaka T
    Kekkaku; 1996 Aug; 71(8):459-64. PubMed ID: 8831191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experience with rifabutin in the treatment of mycobacterial infections.
    De Cian W; Sassella D; Wynne BA
    Scand J Infect Dis Suppl; 1995; 98():22-6. PubMed ID: 8867175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cross-resistance between rifampicin and rifabutin among multi-drug resistant Mycobacterium tuberculosis strains].
    Chikamatsu K; Mizuno K; Yamada H; Mitarai S
    Kekkaku; 2009 Sep; 84(9):631-3. PubMed ID: 19860266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic efficacy of benzoxazinorifamycin KRM-1648 against experimental murine tuberculosis: (1). A study on the efficacy of short course treatment with the intratracheal and intravenous infection model].
    Doi N
    Kekkaku; 1998 Feb; 73(2):53-64. PubMed ID: 9545697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis.
    McGregor MM; Olliaro P; Wolmarans L; Mabuza B; Bredell M; Felten MK; Fourie PB
    Am J Respir Crit Care Med; 1996 Nov; 154(5):1462-7. PubMed ID: 8912765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The tolerability and therapeutic efficacy of rifabutin in the treatment of pulmonary tuberculosis].
    Parola D; Dell'Orso D; Giovagnoli S; Bianconi S; Terzano C
    Recenti Prog Med; 1999 May; 90(5):254-7. PubMed ID: 10380552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tuberculosis in compromised hosts].
    Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Susceptibility to rifabutin and novel fluoroquinolones in Mycobacterium avium complex isolates from patients with sputum culture-positive pulmonary disease who are undergoing standard chemotherapy].
    Tateishi Y; Motone M; Yoshimura K; Miki M; Miki K; Kitada S; Hashimoto H; Hiraga T; Maekura R
    Nihon Kokyuki Gakkai Zasshi; 2010 Nov; 48(11):797-802. PubMed ID: 21141056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Nontuberculous mycobacteriosis; the present status and in the future. 3--(1). The view of development of new drugs against nontuberculous mycobacterial infections].
    Kawahara S; Nagare H
    Kekkaku; 1998 Feb; 73(2):77-82. PubMed ID: 9545700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients.
    Kouanda S; Ouedraogo HG; Cisse K; Compaoré TR; Sulis G; Diagbouga S; Roggi A; Tarnagda G; Villani P; Sangare L; Simporé J; Regazzi M; Matteelli A
    BMC Infect Dis; 2020 Jun; 20(1):449. PubMed ID: 32590942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of KRM 1648 or rifabutin alone or in combination with clarithromycin against Mycobacterium avium complex in human alveolar macrophages.
    Suzuki K; Tsuyuguchi K; Matsumoto H; Yamamoto T; Hashimoto T; Tanaka E; Amitani R; Kuze F
    Int J Tuberc Lung Dis; 1997 Oct; 1(5):460-7. PubMed ID: 9441102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New drugs against tuberculosis and nontuberculous mycobacterial infections: a review].
    Amitani R; Kuze F
    Kekkaku; 1994 Nov; 69(11):711-7. PubMed ID: 7837725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Problem of drug-resistant tuberculosis and the way of its solution].
    Pukhlik BM
    Probl Tuberk; 1999; (6):17-20. PubMed ID: 10715949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current status and perspectives on the development of rifamycin derivative antibiotics].
    Hidaka T
    Kekkaku; 1999 Jan; 74(1):53-61. PubMed ID: 10067056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and evaluation of rifabutin analogs against Mycobacterium avium and H(37)Rv, MDR and NRP Mycobacterium tuberculosis.
    Figueiredo R; Moiteiro C; Medeiros MA; da Silva PA; Ramos D; Spies F; Ribeiro MO; Lourenço MC; Júnior IN; Gaspar MM; Cruz ME; Curto MJ; Franzblau SG; Orozco H; Aguilar D; Hernandez-Pando R; Costa MC
    Bioorg Med Chem; 2009 Jan; 17(2):503-11. PubMed ID: 19119013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of non-tuberculous pulmonary mycobacteriosis].
    Sakatani M; Nakajima Y
    Kekkaku; 2006 Jan; 81(1):35-50. PubMed ID: 16479999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.